

(MHC)', 'hepatitis B virus (HBV)', 'human papillomavirus (HPV)' and 'human immunodeficiency virus type-1 (HIV-1)'.

The change of sequence in Table 1, line 15, from 'FLNVTVHSA' to 'FLNVIVHSA' reflects the correction of a typographical error. The change of sequence in Table 2, line 24, from 'KPLDGETYFTL' to 'KPLDGEYFTL' reflects the correction of a typographical error. Also, the change of sequence in Table 4, line 34, from 'VLQWRFD SRL' TO 'VLQWRFD SRL' reflects the correction of a typographical error. No new matter has been introduced by these changes, as the original PCT application shows the correct sequences.

Lastly, the changes in Table 4 to the protein names were only stylistic. These changes were made for consistency and to reflect the convention of naming in the Art. Thus changes from 'Gp120' to 'gp120' or '(Nef' to 'Nef' simply reflect either changes to conventional norms or the correction of typographical errors. No new matter has been introduced by such changes. The changes in Table 6, from 'melanome' to 'melanoma', and 'carcinome' to 'carcinoma' reflect changes of French spellings to English spellings of these terms.

No new matter has been added by virtue of the amendments made to the specification. The SEQ ID NO: designators have been added to identify sequences as originally filed.


Also submitted with this Amendment is a Sequence Listing containing SEQ ID NO:1 through SEQ ID NO:276 and a "Statement to Support the Filing and Submission of the Sequence Listing in accordance with 37 C.F.R. §§1.821-1.825". No further fee is believed due with this submission.

Attached hereto is a marked-up version of the changes made to the claims and specification in this amendment. The attached pages are captioned "**Version with Markings to Show Changes Made**".

Respectfully submitted,

BIERMAN, MUSERLIAN & LUCAS

Date: March 14, 2002

By: 
Charles A. Muserlian
Registration No. 19,683

Correspondence Address:

BIERMAN, MUSERLIAN AND LUCAS, L.L.P
600 Third Avenue, 28th Floor
New York, New York 10016
Telephone: (212) 661-8000
Facsimile: (212) 661-8002

Version with Markings to Show Changes Made

IN THE SPECIFICATION:

The specification has been amended as follows:

On page 1, line 31 has been replaced as follows:

CTL epitope, of the portion 830-843 of the tetanic (tetanus) toxin, as auxiliary T

On page 2, line 15 has been replaced as follows:

pattern to class I [CMH] MHC

On page 6, line 5 has been replaced as follows:

QYIKANSKFIGITE (SEQ ID NO: 1)

On page 6, line 15 has been replaced as follows:

[(VBH)] (HBV) or the papillomavirus, or the protein p53 as well

On page 6, line 23 has been replaced as follows:

- epitopes of the E₆ or E₇ proteins of the human papillomavirus [(VPH)] (HPV)

On page 6, line 32 has been replaced as follows:

(GQAEPDRAHNIVTF (SEQ ID NO:2)) containing HLA A2, A24, B7 and B18

epitopes.

On page 9, line 30 has been replaced as follows:

Pam-K(Pam)-SS-QYIKANSKFIGITE-AAA-AAGIGILTV (SEQ ID NO:3)

On page 9, line 32 has been replaced as follows:

Pam-K(Pam)-SS-QYIKANSKFIGITE-RGR-AAGIGILTV (SEQ ID NO:4)

On page 9, line 34 has been replaced as follows:

Pam-K(Pam)-GR-QYIKANSKFIGITE-RGR-AAGIGILTV (SEQ ID NO:5)

On page 12, line 17 has been replaced as follows:

H-K(Pam)-SS-QYIKANSKFIGITE-RGR-AAGIGILTV (SEQ ID NO:6)

On page 12, line 26 has been replaced as follows:

H-K(Pam)-GR-QYIKANSKFIGITE-RGR-AAGIGILTV (SEQ ID NO:7)

On page 17, line 23 has been replaced as follows:

hydrazinopeptide: K(NH₂) ILKEPVHGV (SEQ ID NO:8)-OH/epitope MHCI-POL HIV-1

On page 17, lines 24-25 have been replaced as follows:

aldehyde peptide: CHOCO- (RTPPAYRPPNAPILK (SEQ ID NO:9)) (Pam)-NH₂/epitope MHCII-HBVc

Beginning on page 25, line10, through page 26, Table 1 has been replaced as follows:

TABLE 1: BCR-ABL epitopes

Peptide	Sequence	Binding with HLA
247-255	EDAELNPRF (<u>SEQ ID NO:10</u>)	B44
488-496	SELDLEKGL (<u>SEQ ID NO:11</u>)	B44
768-776	DELEAVPNI (<u>SEQ ID NO:12</u>)	B44
901-934 b2a2	KEDALQRPV (<u>SEQ ID NO:13</u>)	B44
902-935 b2a2	EDALQRPVA (<u>SEQ ID NO:14</u>)	B44
986-994	GEKLRVLGY (<u>SEQ ID NO:15</u>)	B44
1176-1184	EDTMEVEEF (<u>SEQ ID NO:16</u>)	B44
1252-1260	MEYLEKKNF (<u>SEQ ID NO:17</u>)	B44
1691-1699	NEEADEVF (<u>SEQ ID NO:18</u>)	B44
49-57	VNQERFRMI (<u>SEQ ID NO:19</u>)	B8
580-588	LFQKLASQL (<u>SEQ ID NO:20</u>)	B8

722-730	ARKLRHVFL (<u>SEQ ID NO:21</u>)	B8
786-794	ALKIKISQI (<u>SEQ ID NO:22</u>)	B8
886-893	CVKLQTVH (<u>SEQ ID NO:23</u>)	B8
928-936 b3a2	KALQRPVAS (<u>SEQ ID NO:24</u>)	B8
1830-1838	GAKTKATSL (<u>SEQ ID NO:25</u>)	B8
1975-1983	IQQMRNKFA (<u>SEQ ID NO:26</u>)	B8
1977-1984	QMRNKFAF (<u>SEQ ID NO:27</u>)	B8
252-260	NPRFLKDNL (<u>SEQ ID NO:28</u>)	B7
329-338	TPDCSSNENL (<u>SEQ ID NO:29</u>)	B7
693-701	TPRRQSMTV (<u>SEQ ID NO:30</u>)	B7
1058-1066	SPGQRSISL (<u>SEQ ID NO:31</u>)	B7
1196-1205	HPNLVQLLGV (<u>SEQ ID NO:32</u>)	B7
1560-1569	SPKPSNGAGV (<u>SEQ ID NO:33</u>)	B7
1717-1725	KPLRRQVTV (<u>SEQ ID NO:34</u>)	B7
1878-1884	SPAPVPSTL (<u>SEQ ID NO:35</u>)	B7
36-44	ERCKASIRR (<u>SEQ ID NO:36</u>)	B27
71-79	DRQRWGFFRR (<u>SEQ ID NO:37</u>)	B27
575-583	QRVGDLFQK (<u>SEQ ID NO:38</u>)	B27
834-842	FRVHSRNGK (<u>SEQ ID NO:39</u>)	B27
642-650	LLYKPVDRV (<u>SEQ ID NO:40</u>)	A2
684-692	FLSSINEEI (<u>SEQ ID NO:41</u>)	A2
708-716	QLLKDSFMV (<u>SEQ ID NO:42</u>)	A2
714-722	FMVELVEGA (<u>SEQ ID NO:43</u>)	A2
817-825	KLSEQESLL (<u>SEQ ID NO:44</u>)	A2
881-889	MLTNSCVKL (<u>SEQ ID NO:45</u>)	A2
908-917	GLYGFLNVIV (<u>SEQ ID NO:46</u>)	A2
912-920	FLNV[T]IVHSA (<u>SEQ ID NO:47</u>)	A2
1240-1248	VLLYMATQI (<u>SEQ ID NO:48</u>)	A2
1903-1911	FIPLISTRV (<u>SEQ ID NO:49</u>)	A2
1932-1940	VVLDSTEAL (<u>SEQ ID NO:50</u>)	A2
50-58	NQERFRMIY (<u>SEQ ID NO:51</u>)	A1
223-231	VGDASRPPY (<u>SEQ ID NO:52</u>)	A1
549-558	KVPELYEIHK (<u>SEQ ID NO:53</u>)	A3/A11
583-591	KLASQLGVY (<u>SEQ ID NO:54</u>)	A3/A11
715-724	MVELVEGARK (<u>SEQ ID NO:55</u>)	A3/A11
916-923	IVHSATGFK (<u>SEQ ID NO:56</u>)	A3/A11
620-928 b3a2	ATGFKQSSK (<u>SEQ ID NO:57</u>)	A3/A11
924-932 b3a2	KQSSKALQR (<u>SEQ ID NO:58</u>)	A3/A11
1156-1165	EVYEGVWKKY (<u>SEQ ID NO:59</u>)	A3/A11
1311-1320	SLAYNKFSIK (<u>SEQ ID NO:60</u>)	A3/A11
1499-1509	NLFSALIKK (<u>SEQ ID NO:61</u>)	A3/A11

1724-1734	TVAPASGLPHK (SEQ ID NO:62)	A3/A11
1905-1914	LISTRVSLRK (SEQ ID NO:63)	A3/A11
1922-1930	RIASGAITK (SEQ ID NO:64)	A3/A11

On page 27, Table 2 has been replaced as follows:

TABLE 2: p53 epitopes

- p53 epitopes binding with HLA-A1:

RVEGNLARVEY (196-205) (SEQ ID NO:65)

GSDCTTIHY (226-234) (SEQ ID NO:66)

- p53 epitopes binding with HLA-A2:

LLPENNVLSP (25-35) (SEQ ID NO:67)

RMPEAAPPV (65-73) (SEQ ID NO:68)

RMPEAAPRV (SEQ ID NO:69)

ALNKMFCQL (129-137) (SEQ ID NO:70)

STPPPGTRV (149-157) (SEQ ID NO:71)

GLAPPQHLIRV (187-197) (SEQ ID NO:72)

LLGRNSFEV (264-272) (SEQ ID NO:73)

PLDGEYFTL (322-330) (SEQ ID NO:74)

- p53 epitopes binding with HLA-A3:

RVRAMAIYK (156-164) (SEQ ID NO:75)

RRTEENLR (282-290) (SEQ ID NO:76)

ELPPGSTKR (298-306) (SEQ ID NO:77)

- p53 epitopes binding with HLA-B7:

LPENNVLSP (26-35) (SEQ ID NO:78)

APRMPEAAPPV (63-73) (SEQ ID NO:79)

APRMPEAAPRV (SEQ ID NO:80)

APPQHLIRV (189-197) (SEQ ID NO:81)

RPILTIITL (249-257) (SEQ ID NO:82)

KPLDGE[T]YFTL (321-330) (SEQ ID NO:83)

- p53 epitopes binding with HLA-B8:

CQLAKTCPV (135-143) (SEQ ID NO:84)

GLAPPQHIL (187-195) (SEQ ID NO:85)

NTFRHSVVV (210-218) (SEQ ID NO:86)

- p53 epitopes binding with HLA-B51:

LLPENNVLSP (25-35) (SEQ ID NO:87)

RMPEAAPPV (65-73) (SEQ ID NO:88)

LIRVEGNLRV (194-203) (SEQ ID NO:89)

On page 28, at lines 1 through 13, Table 3 has been replaced as follows:

TABLE 3: E₆ and E₇ protein epitopes

YMLDLQPETT (E7 11-20) (SEQ ID NO:90)
 LLMGTLGIV (E7 82-90) (SEQ ID NO:91)
 TLGIVCPI (E7 86-93) (SEQ ID NO:92)
 TIHDIILECV (E6 29-38) (SEQ ID NO:93)
 KLPQLCTEL (E6 18-26) (SEQ ID NO:94)
 RPPKLPQL (E6 8-15) (SEQ ID NO:95)
 LRREVDFAFRDLCIVYRDGNPY (E6 45-67) (SEQ ID NO:96)
 ISEYRHYCY (E6 80-88) (SEQ ID NO:97)
 EKQRHLDKKQRFHNIRGRWT (E6 121-140) (SEQ ID NO:98)
 GQAEPDRAHYNIVTF (E7 43-57) (SEQ ID NO:99)
 QAEPDRAHY (E7 44-52) (SEQ ID NO:100)
 EPDRAHYNIV (E7 46-55) (SEQ ID NO:101)

On page 28, beginning at line 15, through the end of page 32, Table 4 has been replaced as follows:

TABLE 4: [VIH] HIV-1 virus epitopes

HLA-A1

[I]Nef 96-106: GLEGLIHSQRR (SEQ ID NO:102)
 [I]Nef 121-128: FPDWQNYT (SEQ ID NO:103)
 [(NEF)]Nef 137-145: LTFGWCYKL (SEQ ID NO:104)
 [I]Nef 184-191: RFDSRLAF (SEQ ID NO:105)
 [I]Nef 195-202: ARELHPEY (SEQ ID NO:106)

HLA-A2

[G]gp120 121-129: KLTPLCVTL (SEQ ID NO:107)
 [P]p17 77-85: SLYNTVATL (SEQ ID NO:108)
 RT 200-208: ALVEICTEM (SEQ ID NO:109)
 RT 275-285: VLDVGDAYFSV (SEQ ID NO:110)
 RT 346-354: KIYQYMDDL (SEQ ID NO:111)
 RT 368-376: KIEELRQHL (SEQ ID NO:112)
 RT 376-387: LLRWGLTTPDK (SEQ ID NO:113)
 RT 476-484: ILKEPVHGV (SEQ ID NO:114)
 RT 588-596: PLVKLWYQL (SEQ ID NO:115)
 RT 683-692: ELVNQDEQL (SEQ ID NO:116)
 Nef 136-145: PLTFGWCFKL (SEQ ID NO:117)

Nef 180-189: VL[O]QWRFD SRL (SEQ ID NO:118)
 Nef 190-198: ALHHVAREL (SEQ ID NO:119)
 [G]gp41 818-826: SLLNATVDI (SEQ ID NO:120)
 [P]p24 185-193: DLNTMLNTV (SEQ ID NO:121)
 RT 346-354: VIYQYMDDL (SEQ ID NO:122)
 RT 588-596: PLVKLWYQL (SEQ ID NO:123)
 Pro 143-152: VLVGPTPVNI (SEQ ID NO:124)
 [(G]gp 120 37-44: TVYYGVPV (SEQ ID NO:125)
 [(G]gp120 115-122: SLKPCVKL (SEQ ID NO:126)
 [(G]gp120 313-321: RIQRGPGRA (SEQ ID NO:127)
 [(G]gp120 197-205: TLTSCNTSV (SEQ ID NO:128)
 [(G]gp120 428-435: FINMWQEV (SEQ ID NO:129)
 [(G]gp41 836-844: VVQGAYRAI (SEQ ID NO:130)
 [(I]p24 219-228: HAGPIAPGQM (SEQ ID NO:131)
 [(P]p15 422-431: QMKDCTERQA (SEQ ID NO:132)
 [(I]p15 448-456: FLQSRPETA (SEQ ID NO:133)
 [(I]RT 681-691: ESELVNQIIEG (SEQ ID NO:134)

HLA-A3

[P]p17 18-26: KIRLRPGGK (SEQ ID NO:135)
 [P]p17 20 28:RLRPGGKKK (SEQ ID NO:136)
 RT 200-210: ALVEICTEMEK (SEQ ID NO:137)
 RT 325-333:AIFQSSMTK (SEQ ID NO:138)
 RT 359-368: DLEIGQHRTK (SEQ ID NO:139)
 Nef 73-82: QVPLRPMTYK (SEQ ID NO:140)
 [G]gp120 37-46: TVYYGVPVWK (SEQ ID NO:141)
 [G]gp41 775-785: RLRDLLLIVTR (SEQ ID NO:142)
 [P]p17 18-26: KIRLRPGGK (SEQ ID NO:143)

HLA-A11

RT 325-333: AIFQSSMTK (SEQ ID NO:144)
 RT 507-517: QIYQEPFKNLK (SEQ ID NO:145)
 Nef 73-82: QVPLRPMTYK (SEQ ID NO:146)
 Nef 84-92: AVDLSHFLK (SEQ ID NO:147)
 p24 349-359: ACQVGPGPHK (SEQ ID NO:148)
 [P]p17 83-91:ATLYCVHQR (SEQ ID NO:149)

HLA-A24 (A9)

[G]gp 120 52-61: LFCASDAKAY (SEQ ID NO:150)
 [G]gp41 591-598: YLKDQQLL (SEQ ID NO:151)
 or 590-597: RYLKDQQLL (SEQ ID NO:152)
 [(I]RT 484-492: VYYDPSKDL (SEQ ID NO:153)
 [(I]RT 508-516: IYQEPFKNL (SEQ ID NO:154)
 [(I]RT 681-691: ESELVNQIIEG (SEQ ID NO:155)

HLA-A25 (A10)[P]p24 203-212: ETINEEAAEW (SEQ ID NO:156)**HLA-A26 (A10)**[P]p24 167-175: EVIPMFSAL (SEQ ID NO:157)**HLA-A30 (A19)**[(G]gp41 845-852: RAIRHIPRR (SEQ ID NO:158)**HLA-A31 (A19)**[G]gp41 775-785: RLRDLLLIVTR (SEQ ID NO:159)**HLA-A32 (A19)**[G]gp120 424-432: RIKQIINMW (SEQ ID NO:160)[G]gp41 774-785: HRLRDLLLI (SEQ ID NO:161)RT 559-568: PIQKETWETW (SEQ ID NO:162)**HLA-A33 (A19)**[(P]p24 266-275: IILGLNKIVR (SEQ ID NO:163)**HLA-B7**RT 699-707: YLAWVPAHK (SEQ ID NO:164)Nef 68-77:FPVTQVPLR (SEQ ID NO:165)Nef 128-137: TPGPGVRYPL (SEQ ID NO:166)[(G]gp120 303-312: RPNNNTRKSI (SEQ ID NO:167)[(G]gp41 848-856: IPRRIRQGL (SEQ ID NO:168)RT 699-77: YLAWVPAHK (SEQ ID NO:169)**HLA-B8**[G]gp120 2-10: RVKEYQHL (SEQ ID NO:170)[P]p17 24-32: GGKKKYKLK (SEQ ID NO:171)Nef 90-97: FLKEKGGL [=] (SEQ ID NO:172)[P]p24 259-267: GEIYKRWII (SEQ ID NO:173)[G]gp41 591-598: YLKDQQLL (SEQ ID NO:174)[(G]gp41 849-856: PRRIRQGL (SEQ ID NO:175)or 851-859: RIRQGLERIL (SEQ ID NO:176)[(P]p24 329-337: DCKTILKAL (SEQ ID NO:177)[(I]RT 185-193: GPKVKQWPL (SEQ ID NO:178)[(I]Nef 182-189: EWRFD SRL (SEQ ID NO:179)**HLA-B14**[G]gp41 589-597: ERYLKDQQL (SEQ ID NO:180)[P]p24 298-306: DRFYKTLRA (SEQ ID NO:181)[(P]p24 183-191 ? : DLNTMLNTV (SEQ ID NO:182)[(I]p24 304-313: LRAEQASVQEV (SEQ ID NO:183)[(I]p24 305-313: RAEQASVQEV (SEQ ID NO:184)**HLA-B18**Nef 135-143: YPLTFGW CY (SEQ ID NO:185)Nef 135-143: YPLTFGWCF (SEQ ID NO:186)

HLA-B27

[P]p24 263-272: KRWIILGLNK (SEQ ID NO:187)
 Nef 73-82: QVPLRPMTYK (SEQ ID NO:188)
 Nef 134-141: RYPLTFGW (SEQ ID NO:189)
 or 133-141: YPLTFGW (SEQ ID NO:190)
 [G]gp41 589-597: ERYLKDQQL (SEQ ID NO:191)
 [(G]gp41 791-800: GRRGWEALKY (SEQ ID NO:192)

HLA-B35

[G]gp120 78-86: DPNPQEVVL (SEQ ID NO:193)
 [G]gp120 257-265: RPVVSTQLL (SEQ ID NO:194)
 RT 285-294: VPLDKDFRKY (SEQ ID NO:195)
 RT 323-331: SPAIFQSSM (SEQ ID NO:196)
 RT 342-350: NPDIVIYQY (SEQ ID NO:197) (consensus clade B)
 RT 460-468: IPLTEEAEL (SEQ ID NO:198)
 RT 598-608: EPIVGAETFY (SEQ ID NO:199)
 Nef 68-76: FPVRPQVPL (SEQ ID NO:200)
 Nef 74-81: VPLRPMTY (SEQ ID NO:201)
 [G]gp41 611-619: TAVPWNASW (SEQ ID NO:202)
 [G]gp120 42-52: VPVWKEATTTL (SEQ ID NO:203)
 [P]p17 124-132: NSSQVSQNY (SEQ ID NO:204) (consensus clade B)
 [P]p24 254-262: PPIPVGELIY (SEQ ID NO:205) (consensus clade B)

HLA-B37

Nef 120-128: YFPDWQNYT (SEQ ID NO:206)

HLA-B44 (B12)

[P]p24 178-186: SEGATPQDL (SEQ ID NO:207)
 [(P]p24 175-184: LESGATPQDL (SEQ ID NO:208)

HLA-B51 (B5)

gp[-]41 562-570: RAIEAQQHL (SEQ ID NO:209)
 RT 200-208: ALVEICTEM (SEQ ID NO:210)
 RT 209-217: EKEGKISKI (SEQ ID NO:211)
 RT 295-302: TAFTIPSI (SEQ ID NO:212)

HLA-B52 (B5)

Nef 190-198: AFHHVAREL (SEQ ID NO:213)

HLA-B55 (B22)

[G]gp120 42-51: VPVWKEATTTL (SEQ ID NO:214)

HLA-B57 and B58 (B17)

[P]p24 240-249: TSLTQEQIGW (SEQ ID NO:215)
 Nef 116-125: HTQGYFPDWQ (SEQ ID NO:216)
 or 116-124: HTQGYFPDW (SEQ ID NO:217)
 Nef 120-128: YFPDWQN (SEQ ID NO:218)
 [(P]p24 147-155: ISPRTLNAW (SEQ ID NO:219)

[(P)p24 164-172: FSPEVIPMF (SEQ ID NO:220)**HLA-Bw62 (B15)**[P]p17 20-29: RLRPGGKKKY (SEQ ID NO:221)[P]p24 268-277: LGLNKIVRMY (SEQ ID NO:222)RT 427-438: LVGKLNWASQIY (SEQ ID NO:223)Nef 84-91: AVDLSHFL (SEQ ID NO:224)Nef 117-127: TQGYFPDWQNY (SEQ ID NO:225)**HLA-Cw4**gp120 380-388: SFNCGGEFF (SEQ ID NO:226)**HLA-Cw8**RT 663-672: VTDSQYALGI (SEQ ID NO:227)[P]p24 305-313: RAEQASQEV (SEQ ID NO:228)Nef 82-91: KAALDLSHPL (SEQ ID NO:229)**HLA-Cw?**[P]p24 308-316: QATQEVKNW (SEQ ID NO:230)

On page 33, beginning at line 15, through the end of page 32, Table 5 has been replaced as follows:

TABLE 5 – Human melanoma epitopes

Gene/protein	Restriction MHC	Peptide	Position of amino-acids
Tyrosinase	HLA-A2	MLLAVLYCL (<u>SEQ ID NO:231</u>)	1-9
	HLA-A2	YMNGTMSQV (<u>SEQ ID NO:232</u>)	369-377
		YMDGTMSQV (<u>SEQ ID NO:233</u>)	
	HLA-A24	AFLPWHRLF (<u>SEQ ID NO:234</u>)	206-214
	HLA-B44	SEIWRDIDF (<u>SEQ ID NO:235</u>)	192-200
Pmel17 ^{gp100}	HLA-A2	KTWGQYWQV (<u>SEQ ID NO:236</u>)	154-162
	HLA-A2	AMLGHTMEV (<u>SEQ ID NO:237</u>)	177-186
	HLA-A2	MLGHTMEV (<u>SEQ ID NO:238</u>)	178-186
	HLA-A2	ITDQVPFSV (<u>SEQ ID NO:239</u>)	209-217
	HLA-A2	YLEPGPVTA (<u>SEQ ID NO:240</u>)	280-288
	HLA-A2	LLDGTATLRL (<u>SEQ ID NO:241</u>)	457-466
	HLA-A2	VLYRYGSFSV (<u>SEQ ID NO:242</u>)	476-485
	HLA-A2	SLADTNSLAV (<u>SEQ ID NO:243</u>)	570-579
	HLA-A3	ALLAVGATK (<u>SEQ ID NO:244</u>)	17-25

Gene/protein	Restriction MHC	Peptide	Position of amino-acids
Melan-A ^{MART-1}	HLA-A2	(E)AAGIGILTV (SEQ ID NO:245)	(26)2[(7)]-35
	HLA-A2	ILTVILGVL (SEQ ID NO:246)	32-40
Gp ^{75TRP-1}	HLA-A31	MSLQRQFLR (SEQ ID NO:247)	
TRP-2	HLA-A31	LLGPGRPYR (SEQ ID NO:248)	197-205

On page 33, Table 6 has been replaced as follows:

TABLE 6 – Tumor epitopes resulting from mutations

Gene/protein	Tumor	Restriction MHC	Peptide	Position of amino-acids
MUM-1	Melanom[e]a	HLA-B44	EEKLIVVLF (SEQ ID NO:249)	30-38
CDK4	Melanom[e]a	HLA-A2	ACDPHSGHFV (SEQ ID NO:250)	23-32
β -catenin	Melanom[e]a	HLA-A24	SYLDSGIHF (SEQ ID NO:251)	29-37
CASP-8	Squamous head and neck carcinom[e]a	HLA-B35	FPSDSWCYF (SEQ ID NO:252)	476-484

On page 34, Table 7 has been replaced as follows:

TABLE 7 – Antigens common to various tumors

Gene	Tissue where normal expression takes place	Restriction MHC	Antigenic peptide	Position of amino-acids
MAGE-1	Testicles	HLA-A1	EADPTGHSY (SEQ ID NO:253)	161-169
MAGE-3	Testicles	HLA-Cw16	SAYGEPRKL (SEQ ID NO:254)	230-238
		HLA-A1	EVDPIGHLV (SEQ ID NO:255)	168-176
		HLA-A2	FLWGPRLV (SEQ ID NO:256)	271-279
		HLA-B44	MEVDPIGHLV (SEQ ID NO:257)	167-176
BAGE	Testicles	HLA-Cw16	AARAVFLAL (SEQ ID NO:258)	2-10
GAGE-1/2	Testicles	HLA-Cw6	YRPRPRRY (SEQ ID NO:259)	9-16

RAGE-1	Retina	HLA-B7	SPSSNRIRNT (SEQ ID NO:260)	11-20
GnTV	None	HLA-A2	VLPDVFIRC (SEQ ID NO:261)	38-64

On page 35, Table 8 has been replaced as follows:

TABLE 8: USED PEPTIDES AND LIPOPEPTIDES

Designation	Position	Amino-acid sequences	Restriction MHC-I	Reference
Peptides HIV				
GAG	77-85	SLYNTVATL (SEQ ID NO:262)	HLA-A2.01	(6)
POL	476-484	ILKEPVHGV (SEQ ID NO:263)	HLA-A2.01	(5)
POL	346-354	VIYQYMDDL (SEQ ID NO:264)	HLA-A2.01	(2)
POL	342-350	NPDIVYQY (SEQ ID NO:265)	HLA-B35	(4)
POL	343-350	PDIVYQY (SEQ ID NO:266)	HLA-B44	non described
POL	347-354	FYQYMDDL (SEQ ID NO:267)	HLA-A24	non described
POL	345-354	IVIYQYMDDL (SEQ ID NO:268)	HLA-A2	non described
NEF	68-76	FPVTPQVPL (SEQ ID NO:269)	HLA-B7-B35	(3)
NEF	71-79	TPQVPLRPM* (SEQ ID NO:270)	HLA-B35	non described
NEF	74-81	VPLRPMTY (SEQ ID NO:271)	HLA-B35	(1)
NEF	73-82	QVPLRPMTYK (SEQ ID NO:272)	HLA-A3-A11	(1)
Lipoptides HIV				

TT-GAG	77-85 Palm-K-GR QYIKANSKFIGITE RGR SLYNTVATL (SEQ ID NO 273)	HLA-A2.01	
TT-POL1	476-484 Palm-K-GR QYIKANSKFIGITE RGR ILKEPVHGV (SEQ ID NO 274)	HLA-A2.01	
TT-POL2	Palm-K-GR QYIKANSKFIGITE RGR NPDI VIYQYMDDL (SEQ ID NO 275) multi-epitope	Multi HLA	
TT-NEF	Palm-K-GR QYIKANSKFIGITE RGR FPVTP QVPLRPMTYK (SEQ ID NO:276) multi-epitope	Multi HLA	
Auxiliary T peptide			
Tetanic toxine	830-843 QYIKANSKFIGITE (SEQ ID NO:1)	HLA-DR, H-2 K ^b	

In the Claims:

Claim 38 has been amended as follows:

38. A lipopeptide of claim 23 wherein the auxiliary T epitope is the 830-843 peptide of tetanic toxin with the sequence QYIKANSKFIGITE (SEQ ID NO:1).